Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults With Advanced Solid Tumors

NCT06809114 is registered in ClinicalTrials.gov with Axcynsis Therapeutics Pte Ltd as lead sponsor.

NCT NCT06809114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06809114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults With Advanced Solid Tumors
Lead sponsor
Axcynsis Therapeutics Pte Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
January 14, 2026
Completion date
August 31, 2028
Enrollment
83 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor